Projects per year
Personal profile
Headline
Resident
Fingerprint
Dive into the research topics where Douglas Tremblay is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Active
-
New Treatments for Myelofibrosis
Tremblay, D. & Mesa, R., Feb 2023, In: Current Treatment Options in Oncology. 24, 2, p. 61-75 15 p.Research output: Contribution to journal › Article › peer-review
-
Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs
Liu, A., Naymagon, L. & Tremblay, D., Jan 2023, In: Cancers. 15, 1, 11.Research output: Contribution to journal › Review article › peer-review
Open Access -
Addressing symptom burden in myeloproliferative neoplasms
Tremblay, D. & Mesa, R., Jun 2022, In: Best Practice and Research in Clinical Haematology. 35, 2, 101372.Research output: Contribution to journal › Review article › peer-review
-
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database
Rippel, N., Tremblay, D., Zubizarreta, N., Podoltsev, N., Gotlib, J., Heaney, M., Kuykendall, A., O'Connell, C., Shammo, J. M., Fleischman, A., Kremyanskaya, M., Hoffman, R., Mesa, R., Yacoub, A. & Mascarenhas, J., Aug 2022, In: Leukemia Research. 119, 106903.Research output: Contribution to journal › Article › peer-review
-
Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine
Feld, J., Tremblay, D., Navada, S. C. & Silverman, L. R., 2022, (Accepted/In press) In: Leukemia and Lymphoma.Research output: Contribution to journal › Review article › peer-review
Press/Media
-
Addition of venetoclax to azacitidine improves outcomes for subset of patients with AML
13/12/21
1 item of Media coverage
Press/Media
-
Most patients with AML, myelodysplastic syndrome seropositive after two COVID vaccine doses
12/12/21
1 item of Media coverage
Press/Media
-
Ivosidenib regimen extends OS, EFS for acute myeloid leukemia subset
12/12/21
1 item of Media coverage
Press/Media